Bristol Myers Squibb (NYSE:BMY) Given New $73.00 Price Target at JPMorgan Chase & Co.

Bristol Myers Squibb (NYSE:BMY) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 12.10% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Guggenheim reiterated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Truist Financial reaffirmed a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $63.00.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE BMY traded up $0.26 during mid-day trading on Friday, reaching $65.12. 6,500,196 shares of the company traded hands, compared to its average volume of 12,226,977. The company’s fifty day moving average is $57.90 and its two-hundred day moving average is $58.29. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $65.66. The stock has a market cap of $132.99 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the prior year, the business earned $1.46 earnings per share. The company’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb will post 6.34 earnings per share for the current year.

Institutional Investors Weigh In On Bristol Myers Squibb

Hedge funds have recently added to or reduced their stakes in the stock. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth $25,000. Bayban bought a new position in Bristol Myers Squibb in the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q2 results exceeded expectations: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus estimates of $11.74 billion. Revenue increased 5.7% year over year, while EPS rose from $1.46 in the prior-year quarter. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year EPS of $6.75 to $7.00 and revenue of $49 billion to $50 billion, above consensus estimates of approximately $6.31 EPS and $47.3 billion in revenue. BMY Q2 earnings beat estimates and 2026 view raised
• Positive Sentiment: Growth products are gaining traction: Eliquis sales were a major contributor, while Camzyos, Reblozyl, Opdivo Qvantig, Breyanzi and other newer medicines helped the growth portfolio reach roughly 60% of revenue. Management also highlighted pipeline progress. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Analyst support improved: Truist reaffirmed its Buy rating and increased its price target from $65 to $70, implying additional upside from recent levels.
• Neutral Sentiment: Some analysts remain cautious, citing valuation after BMY’s recent rally and the need for continued execution to replace older products.
• Negative Sentiment: Risks remain: Legacy portfolio declines from patent expirations continue, while Opdivo declined and readouts for Milvexian and Cobenfy were delayed. Elevated put-option activity also indicates some investors are hedging downside risk.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.